低分子肝素联合阿司匹林治疗抗磷脂抗体引起的复发性流产的临床效果分析

doi:10.3969/j.issn.1006-6233.2018.03.019

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (1349 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical efficacy of low molecular weight heparin combined with aspirin in the treatment of recurrent spontaneous abortion caused by antiphospholipidantibodies. Methods: 88 patients with recurrent spontaneous abortion caused by anti-phospholipid antibody were selected from December 2015 to December 2017 in our hospital. Patients were divided into control group (n = 44) and observation group (n = 44) The patients in the control group and observation group were treated with aspirin and low molecular weight heparin together with aspirin, respectively. The clinical effects of the two groups were compared. Results: After treatment, the total effective rate in the observation group and the control group after treatment was 88.64% and 65.91%, respectively. The difference between the two groups was statistically significant (χ⁼ 6.47, P <0.05). The observation group and the control group were pregnant There was no significant difference in the incidence of complications among the two groups (P> 0.05). After treatment, E2 and P levels in both groups were significantly improved, but the improvement in observation group was significantly better than that in control group (P <0.05). After treatment, the levels of IFN-γ, IL-4 and IFN-γ / IL-4 in the observation group were significantly better than those in the control group (P <0.05). Conclusion: Low molecular weight heparin combined with aspirin in patients with recurrent spontaneous abortion caused by antiphospholipid antibodies has a significant clinical effect, which is helpful for the expression of the hormone and the enhancement of immunity in patients, and also helps to improve the pregnancy outcome of patients with high safety. It is worth clinical promotion.

Key words： Low molecular weight heparin Aspirin Antiphospholipid antibodies Recurrent pregnancy loss

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Shuyun
	ZHANG Hong
	WANG Yunjie
	et al

Cite this article:

ZHANG Shuyun,ZHANG Hong,WANG Yunjie, et al. Clinical Analysis of Low Molecular Weight Heparin and Aspirin in Treating Recurrent pregnancy loss Caused by Antiphospholipid Antibodies[J]. HeBei Med, 2018, 24(3): 422-426.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.03.019 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I3/422

[1] 廖红玉.阿司匹林联合地塞米松孕前干预D2聚体升高型复发性流产的疗效分析[J].中国计划生育和妇产科,2015,7(7):63~65,68.
[2] Asopa V, Cobain W, Martin D, et al. Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty[J]. ANZ Surg,2015, 85(9): 652~657.
[3] Fouda U M, Sayed A M, Ramadan D I, et al. Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome[J]. J ObstetGynaecol,2010, 30(8): 842~846.
[4] 王慧娟,李增彦.肝素联合阿司匹林治疗不明原因复发性流产的疗效观察[J].国际妇产科学杂志,2014,41(2):207~208.
[5] 王统菲,贺立颖,康晓敏,等.阿司匹林对早期复发性流产患者子宫血液动力学的作用[J].上海交通大学学报(医学版),2017,37(4):518~522.
[6] van Hoorn M E, Hague W M, van Pampus M G, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT[J]. Eur ObstetGynecolReprod Biol,2016, 197: 168~173.
[7] 韦懿芸,庞丽红,程晓冰.肝素与阿司匹林在复发性流产中抗磷脂抗体综合征应用的Meta分析[J].广西医科大学学报,2017,34(6):876~880.
[8] Roberge S, Demers S, Nicolaides K H, et al. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis[J]. Ultrasound Obstet Gynecol,2016, 47(5): 548~553.
[9] 王慧娟,唐淑稳.肝素联合阿司匹林用于不明原因复发性流产患者效果观察[J].山东医药,2016,56(32):89~91.
[10] Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome[J]. Int Gynaecol Obstet,2009, 104(3): 223~225.